More than 50 organizations working to end the HIV epidemic in the United States and globally are urging the White House to quickly nominate a leader for the U.S. President’s Emergency Plan for AIDS Relief as the Department of State’s U.S. Global AIDS Coordinator.
A new Clinical Infectious Diseases supplement takes a look back at the public health response to COVID-19 and what can be learned and built upon during the next phase of this pandemic and for future pandemics.
IDSA has developed a joint statement on considerations for COVID-19 vaccination as a condition of employment for healthcare workers with SHEA, HIVMA, the PIDS, APIC, AMDA, & SIDP.
The Infectious Diseases Society of America seeks candidates to serve in the position of editor-in-chief of Clinical Infectious Diseases.
New evidence-based clinical guidelines on the management of Clostridioides difficile infection (CDI) in adults have been developed by a multidisciplinary panel representing IDSA and SHEA.
Today the Global Coalition on Aging (GCOA) and IDSA launched the first-ever global AMR Preparedness Index, a first-of-its-kind evaluation of how the governments of the 11 largest global economies are living up to their commitments to address antimicrobial resistance (AMR).
The renewed introduction in the 117th Congress of the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, a bipartisan House and Senate bill to support the development of new antibiotics and promote their appropriate use, opens a critical opportunity for legislators to combat a growing and global public health crisis.
The IDSA Foundation announces a call for applications for the 2021 Microbial Pathogenesis in Alzheimer’s Disease Grant. The $1.7 million grant, an increase from $1 million in 2020, will fund the advancement of novel research into possible links between infectious diseases and the causation of Alzheimer’s disease.
IDSA Foundation, in collaboration with Johnson & Johnson Innovation – JLABS will host the 2021 IDea Incubator, the premier showcase of technology in the field of infectious diseases and a pitch-style competition that drives innovations across various disciplines with the potential to improve the infectious diseases specialty and patient care.
In separate United Kingdom meetings June 3-5, G7 ministers of health and finance committed their nations to confronting the growing threat of antimicrobial resistance, with meaningful and concrete actions. The concluding documents from the ministers’ meetings directly address priorities promoted by the Infectious Diseases Society of America. With commitments to foster new antibiotic development through international and cross-sectoral collaboration
With significant increases and meaningful investments in U.S. Centers for Disease Control and State Department global health programs, President Biden’s proposed budget for the coming fiscal year offers the promise of renewing our country’s role as a leader of infectious disease responses that can detect, prevent and contain public health threats where they emerge.
The U.S. Centers for Disease Control and Prevention recommendations that fully immunized people can resume most daily activities without masks or concern for physical distancing, except where required by laws and policies, reflect the remarkable protective benefit of COVID-19 vaccines.